Overview

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

Status:
Recruiting
Trial end date:
2022-09-06
Target enrollment:
Participant gender:
Summary
A study to evaluate safety, tolerability and pharmacokinetics of QLS1128 sustained-release tablets and in combination with ritonavir tablets in healthy participants
Phase:
Phase 1
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Ritonavir